. Author manuscript; available in PMC: 2012 Feb 1.

Published in final edited form as: J Abnorm Psychol. 2011 Feb;120(1):98–107. doi: 10.1037/a0020630

Table 1.

Demographics & Clinical Details

	SZ Subjects	Control Subjects	Differences Between Groups
Gender (F/M)	2F/21M	13F/22M	χ2 (1) = 13.52, p < .001
Age: mean (SD), [range]	44.22 (10.3),[23–59]	49.17 (7.65), [24–62]	t(56) = 2.10, p = .041, d = .56^a
Education: mean (SD), [range]	13.35 (2.2), [9–20]	14.40 (1.40), [12–16]	t(56) = 2.26, p = .028, d = .60
WASI IQ: mean (SD), [range]	102 (17.4), [73–138]	111 (10.7), [87–126]	t(40) = 1.97, p = .055, d = .53
Diagnosis: n [%]
Schizoaffective:	8 [34.78%]	-	-
Schizophrenia:	15 [65.22%]	-	-
SZ Subtypes:	Paranoid 7/15	-	-
	Catatonic 1/15	-	-
	Undifferentiated 6/15	-	-
	Residual 1/15	-	-
		-	-
Age of Onset: mean (SD), [range]	19.75 (6.2), [5–31]	-	-
Length of Illness: mean (SD), [range]	26.00 (12.4), [5–47]	-	-
Antipsychotic Medication: n [%] ^b		-	-
Typical:	3 [13.4%]	-	-
Atypical:	18 [78.26%]	-	-
PANSS Symptoms : mean (SD), [range]		-	-
Positive Symptoms	2.44 (1.0), [1 – 4]	-	-
Negative Symptoms	2.23 (.8), [1 – 3.9]	-	-
Disorganized Symptoms	1.74 (.7), [1 – 3.4]	-	-

Cohen’s d effect size

Medication details were obtained for 23/25 patients